Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid, Chronic-Phase 7Recurrence 5Leukemia, Lymphocytic, Chronic, B-Cell 5Breast Neoplasms 5Multiple Myeloma 4Lymphoma, Large B-Cell, Diffuse 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Extranodal NK-T-Cell 3Leukemia, Myeloid, Accelerated Phase 3Immunoblastic Lymphadenopathy 3Hodgkin Disease 3Blast Crisis 3Squamous Cell Carcinoma of Head and Neck 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Mycosis Fungoides 2

Interventions

ganitumab 1Receptor Protein-Tyrosine Kinases 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Rhabdomyosarcoma, Alveolar × Dasatinib × Clear all
NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
14 enrolled 17 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡